MONTREAL — Spiriva Respimat, as an add-on to inhaled corticosteroids or long-acting beta2 agonists, reduced the risk for severe asthma exacerbation in patients across severities of symptomatic asthma ...
Spiriva (tiotropium bromide) is a prescription drug that’s used to treat COPD and asthma. The drug comes in an inhaler. It’s usually used once per day. Spiriva is a prescription drug that comes in two ...
Today, the U.S. Food and Drug Administration approved Striverdi Respimat (olodaterol) inhalation spray to treat patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis ...
INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved once-daily Stiolto™ Respimat ® (tiotropium bromide and olodaterol) ...
This approval was based on efficacy and safety data from the Phase 2 and Phase 3 UniTinA-asthma clinical development program. The Food and Drug Administration (FDA) has approved Spiriva Respimat ...
INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced the publication of new data from the Phase IIIb OTEMTO ® 1&2 trials (NCT01964352 ...
The US Food and Drug Administration (FDA) has approved the long-acting beta-agonist, olodaterol (Striverdi Respimat, Boehringer Ingelheim), for long-term, once-daily maintenance treatment of airflow ...
RIDGEFIELD, Conn. — Boehringer Ingelheim on Wednesday announced that its Striverdi Respimat (olodaterol) inhalation spray in 5-mcg dosage strength is now available by prescription in pharmacies across ...
Boehringer Ingelheim today announced the launch of its new direct-to-consumer platform, “Boehringer Ingelheim Access.” The platform will offer a convenient way for patients in the U.S. to order and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback